Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade) (NASDAQ:SNY)

Core Viewpoint - The analysis revisits Sanofi after a downgrade in early May 2024, which has been validated by market performance, particularly with the S&P 500 showing double-digit returns [1]. Group 1 - Sanofi's stock performance has been under scrutiny following the downgrade, indicating a cautious outlook from analysts [1]. - The S&P 500's double-digit performance highlights a contrasting trend in the broader market compared to Sanofi's recent challenges [1].